We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study / Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:12(2007), pp. 1721-1722. [10.3324/haematol.11345]
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study
Candoni A.;
2007
Abstract
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
| File | Dimensione | Formato | |
|---|---|---|---|
|
4682-Article Text-18651-1-10-20200722.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
195.48 kB
Formato
Adobe PDF
|
195.48 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
